BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24332629)

  • 1. Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
    Kim N; Sohn MJ; Koshino H; Kim EH; Kim WG
    Bioorg Med Chem Lett; 2014 Jan; 24(1):83-6. PubMed ID: 24332629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verrulactones A and B, new inhibitors of Staphylococcus aureus enoyl-ACP reductase produced by Penicillium verruculosum F375.
    Kim N; Sohn MJ; Kim CJ; Kwon HJ; Kim WG
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2503-6. PubMed ID: 22377515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verrulactones D and E with unprecedented skeletons, new inhibitors of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
    Kim N; Sohn MJ; Koshino H; Kim WG
    J Antibiot (Tokyo); 2016 Feb; 69(2):114-8. PubMed ID: 26306815
    [No Abstract]   [Full Text] [Related]  

  • 4. Vinaxanthone, a new FabI inhibitor from Penicillium sp.
    Zheng CJ; Sohn MJ; Kim WG
    J Antimicrob Chemother; 2009 May; 63(5):949-53. PubMed ID: 19282328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
    Kim YG; Seo JH; Kwak JH; Shin KJ
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).
    Sampson PB; Picard C; Handerson S; McGrath TE; Domagala M; Leeson A; Romanov V; Awrey DE; Thambipillai D; Bardouniotis E; Kaplan N; Berman JM; Pauls HW
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5355-8. PubMed ID: 19682901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
    Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
    J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.
    Zheng CJ; Sohn MJ; Lee S; Kim WG
    PLoS One; 2013; 8(11):e78922. PubMed ID: 24312171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complestatin exerts antibacterial activity by the inhibition of fatty acid synthesis.
    Kwon YJ; Kim HJ; Kim WG
    Biol Pharm Bull; 2015; 38(5):715-21. PubMed ID: 25947917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aquastatin A, a new inhibitor of enoyl-acyl carrier protein reductase from Sporothrix sp. FN611.
    Kwon YJ; Fang Y; Xu GH; Kim WG
    Biol Pharm Bull; 2009 Dec; 32(12):2061-4. PubMed ID: 19952429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.
    Kronenberger T; Asse LR; Wrenger C; Trossini GH; Honorio KM; Maltarollo VG
    Future Med Chem; 2017 Feb; 9(2):135-151. PubMed ID: 28128024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.
    Kitagawa H; Kumura K; Takahata S; Iida M; Atsumi K
    Bioorg Med Chem; 2007 Jan; 15(2):1106-16. PubMed ID: 17095231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening of antibacterial compounds by similarity search of Enoyl-ACP reductase (FabI) inhibitors.
    Asse Junior LR; Kronenberger T; Magalhães Serafim MS; Sousa YV; Franco ID; Valli M; Silva Bolzani VD; Monteiro GC; Bruno Prates JL; Kroon EG; Fernandes Mota BE; Santos Ferreira DD; de Oliveira RB; Maltarollo VG
    Future Med Chem; 2020 Jan; 12(1):51-68. PubMed ID: 31729258
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.
    Karlowsky JA; Laing NM; Baudry T; Kaplan N; Vaughan D; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1580-1. PubMed ID: 17220418
    [No Abstract]   [Full Text] [Related]  

  • 15. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
    Mehboob S; Song J; Hevener KE; Su PC; Boci T; Brubaker L; Truong L; Mistry T; Deng J; Cook JL; Santarsiero BD; Ghosh AK; Johnson ME
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1292-6. PubMed ID: 25677657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
    Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
    J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
    Kwon J; Mistry T; Ren J; Johnson ME; Mehboob S
    Bioorg Med Chem; 2018 Jan; 26(1):65-76. PubMed ID: 29162308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
    Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
    J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors.
    Takhi M; Sreenivas K; Reddy CK; Munikumar M; Praveena K; Sudheer P; Rao BN; Ramakanth G; Sivaranjani J; Mulik S; Reddy YR; Narasimha Rao K; Pallavi R; Lakshminarasimhan A; Panigrahi SK; Antony T; Abdullah I; Lee YK; Ramachandra M; Yusof R; Rahman NA; Subramanya H
    Eur J Med Chem; 2014 Sep; 84():382-94. PubMed ID: 25036796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI.
    Ramnauth J; Surman MD; Sampson PB; Forrest B; Wilson J; Freeman E; Manning DD; Martin F; Toro A; Domagala M; Awrey DE; Bardouniotis E; Kaplan N; Berman J; Pauls HW
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5359-62. PubMed ID: 19682900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.